Cizzle Biotechnology Secures US Patent for CIZ1B Lung Cancer Biomarker Test
核心洞察
Cizzle Biotechnology has been granted a US patent by the USPTO covering its core methods to measure the CIZ1B (搜索) biomarker for early-stage lung cancer (搜索) detection.
The patent, titled 'Use of a fibrinogen capture agent to detect a CIZ1B (搜索) variant,' covers a two-step test format developed at the University of York and licensed to Cizzle Bio Inc (搜索) for North America and the Caribbean.
This grant strengthens the company's global patent portfolio following a recent Canadian patent approval and existing European Patent Office protection.
Cizzle Biotechnology Holdings plc (搜索), the UK-based developer of diagnostic tests for early-stage cancer, announced on 12 June 2026 that the U.S. Patent and Trademark Office (USPTO) has allowed a patent application covering the company's core methods to measure the CIZ1B (搜索) lung cancer (搜索) biomarker. The patent grant marks a significant step in the company's strategy to establish a robust intellectual property position in the key North American market.
The newly granted US patent, titled "Use of a fibrinogen capture agent to detect a CIZ1B (搜索) variant," concerns a two-step test format developed by Cizzle at the University of York. This follows the grant of a corresponding patent in Canada, announced on 4 February 2026, and builds upon existing patent protection already secured from the European Patent Office.
Strengthening Commercial Pathways in North America
The two-step test format covered by the USPTO patent is licensed to Cizzle Bio Inc (搜索) (BIO) for use in North America and the Caribbean. According to the company, these new patents strengthen BIO's position as it prepares to launch the test and establish a robust commercial footing for the proprietary technology.
Cizzle Biotechnology's commercial strategy centers on globally licensing its proprietary CIZ1B (搜索) biomarker test for early detection of lung cancer (搜索). The company has stated that its patent portfolio and technology know-how are central to securing future licensing and royalty revenue. Developing a strong patent portfolio in North America is intended to enable BIO to establish a leading market position and supports its partnership programme with specialist clinical laboratories and hospitals, facilitating market penetration to make the test available to as many clinicians and patients as possible.
The Science Behind CIZ1B (搜索)
The CIZ1B (搜索) biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer (搜索) and can be measured in small quantities of blood. The company has developed CIZ1B into a non-invasive, cost-effective blood test to aid in the early detection of lung cancer.
The biomarker test is the product of work by Professor Dawn Coverley, the company's founder and Chief Scientific Officer, and her research team at the University of York, initially supported by both UK industry and charity sector research grants.
European and UK Market Ambitions
Beyond North America, Cizzle Biotechnology intends to secure further licensing partnerships with accredited facilities in the UK and Europe, including the NHS. The company noted that bringing the CIZ1B (搜索) biomarker test to market will provide valuable new solutions applicable to the current NHS cancer plan, which aims to improve cancer survival by diagnosing 75% of cancers at stages 1 and 2 by 2028.
Professor Dawn Coverley, Chief Scientific Officer of Cizzle Biotechnology, commented: "Strengthening of the Company's patent portfolio with this grant by the USPTO is timely and perfectly aligned with recent efforts to take the CIZ1B (搜索) ELISA test format to market with our US partner Cizzle Bio Inc (搜索)."
Cizzle Biotechnology was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021 and has since entered commercial royalty-bearing arrangements to license its proprietary technology, alongside collaborations with centers of excellence in cancer care.